This suggests that PSMA PET, which is promising in treatment response assessment for metastatic prostate cancer, could serve as a complementary tool in assessing treatment response in PSMA-avid hepatic tumors [15]. This evidence concerns the gene FOLH1 and prostate carcinoma.